Managing Systemic Steroids: GI, Endocrine, and Lipid Considerations

Conclusions

• Systemic glucocorticoids do not appear to increase peptic ulcer risk by themselves, so routine PPI prophylaxis is usually unnecessary unless NSAID/aspirin use or other ulcer risk factors are present.
• If acid suppression is needed for steroid-treated patients, H2 blockers may be preferable to PPIs in some cases because of a more favorable long-term safety profile.
• Steroid-related hyperglycemia should be anticipated, monitored early after initiation, and managed with baseline and follow-up glucose assessment to prevent severe complications such as DKA or hyperosmolar crises.
• Adrenal suppression becomes a real concern after prolonged or higher-dose steroid exposure, especially beyond about 20 mg prednisone equivalent for 3 weeks or more.
• Steroids should be tapered cautiously, with cortisol testing used to guide reduction below low doses and with delays in tapering when adrenal recovery is incomplete.
• Patients with prior long-term glucocorticoid exposure may need stress-dose steroids during major illness, surgery, or trauma for up to a year after discontinuation.
• Steroid withdrawal syndrome can mimic adrenal insufficiency but may occur despite normal cortisol, and it is often managed by slowing the taper or temporarily increasing the dose.
• Glucocorticoid therapy can worsen lipid risk indirectly, so cholesterol should be checked and treated aggressively when LDL is elevated.
• Modern ASCVD prevention favors lower LDL targets than older practice, with especially aggressive goals for patients at very high risk, diabetes, or established disease.
• HDL should not be relied on as protective; LDL and apoB-related risk are more important for cardiovascular prevention decisions.
• Patients with autoimmune and inflammatory diseases such as lupus, cutaneous lupus, dermatomyositis, and psoriasis have substantially increased ASCVD risk and often warrant earlier and more intensive lipid treatment.
• Coronary artery calcium scoring and formal ASCVD risk calculators can help identify patients who need more aggressive prevention.
• Statins remain first-line therapy, but ezetimibe and PCSK9 inhibitors provide important additional options when LDL goals are not reached or statins are not tolerated.
• Overall, the talk concludes that steroid complications are manageable with selective GI prophylaxis, proactive endocrine monitoring, careful tapering, and aggressive cardiovascular risk reduction when indicated.